Exact(6)
Large studies are warranted with concurrent chemotherapy to determine the real benefit of PORT.
Further clinical trials were required to assess the benefit of adding concurrent chemotherapy to preoperative radiotherapy.
Nonetheless, the addition of concurrent chemotherapy to PORT significantly increases severe adverse effects [ 4, 5].
Secondly, the addition of concurrent chemotherapy to radiotherapy has improved the survival outcome of patients with loco-regionally advanced NPC [ 16- 18]; however, only 46.6% (131/281) of the patients with Stage III-IVB disease received concurrent chemoradiotherapy [ 13].
Adding concurrent chemotherapy to primary or adjuvant RT increases the risk of dysphagia: a systematic review of TORS for OPSCC showed clear demarcation in swallowing outcomes across a variety of outcome measures in patients who received adjuvant RT alone compared to adjuvant CRT [ 25].
Cisplatin-based induction or concurrent chemotherapy was administered to 122 patients with recurrent T3 4 (rT3–4) and/or bulky gross tumors, including concurrent chemoradiotherapy to 46 patients, induction chemotherapy followed by radiotherapy to 63 patients, and induction and concurrent chemotherapy to 13 patients.
Similar(54)
The results revealed that the addition of concurrent or neoadjuvant-concurrent chemotherapy to IMRT prolonged relapse-free survival (RFS) or DFS for patients with locoregionally advanced NPC, whereas NAC provided no significant benefit for OS, MFS, RFS, and DFS.
The role of induction chemotherapy in addition to concurrent chemotherapy remains to be defined and is currently not the standard of care.
Published clinical trials and retrospective institutional reports have demonstrated that improvements in LRC can be attributed to concurrent chemotherapy and to accelerated fractionation 11– 11.
Induction chemotherapy (IC) was administered to 1073 patients, concurrent chemotherapy (CC) to 1291 patients, IC plus CC (IC + CC) to 1255 patients, and CC plus adjuvant chemotherapy (CC + AC) to 207 patients.
9 We aimed to evaluate whether prophylactic extended-field irradiation with concurrent chemotherapy leads to results better than those obtained by standard pelvic irradiation with concurrent chemotherapy in patients with locally advanced cervical cancer with radiologic negative PALN status.
Write better and faster with AI suggestions while staying true to your unique style.
Since I tried Ludwig back in 2017, I have been constantly using it in both editing and translation. Ever since, I suggest it to my translators at ProSciEditing.

Justyna Jupowicz-Kozak
CEO of Professional Science Editing for Scientists @ prosciediting.com